AzTrials
AzTrials

Brown Adipose TissueTACTICAL-IINCT02964442

Brown Adipose Tissue Activation and Energy Expenditure by Capsinoids Stimulation With Trimodality Imaging Using 18-FDG-PET, Fat Fraction MRI and Infrared Thermography

A study testing Capsinoids and Cold Stimulus in people with Brown Adipose Tissue, run by Singapore Institute of Food and Biotechnology Innovation at 1 site in Singapore.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Brown adipose tissue (BAT) thermogenesis can be assessed by IR thermography, the accompanying increase metabolic rate can be measured by whole body calorimetry and BAT volume can be precisely measured by MRI. Read more about this study

Who is it for?
Ages 21 to 40 yearsHealthy volunteers can take part
Conditions the study is for
Brown Adipose Tissue
What is being tested?
Capsinoids and Cold Stimulus
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
1 siteSingapore
Study dates
23 Oct 2015to 24 Oct 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 to 40 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Overtly healthy with no past history of chronic illnesses
  • Aged 21-40 years old Male and female gender
  • BMI from 18.5 to 29.9 kg/m2 inclusive
  • No prior history of thyroid disease.
  • Euthyroid biochemically with FT4 and TSH in the normal ranges

Who cannot join

  • Recent changes in weight of >5% over the past 6 months.
  • Attempts to lose weight over the past 6 months.
  • Significant changes in diet over the past 6 months.
  • Any use of weight reducing drugs in the past 6 months.
  • Previous weight reducing surgery.
  • Any use of investigational drugs in the past 6 months.
Show all 17Show fewer
  • Subclinical thyroid dysfunction based on thyroid function test.
  • Chronic illnesses such as diabetes mellitus or cancer.
  • You have a known history of thyroid, liver or kidney disease.
  • Use of any prescription medication that cannot be safely discontinued within 14 days prior to study entry.
  • Female subjects who are pregnant.
  • Oral medications affecting brown fat activity (eg. alpha agonists or blockers, beta agonists or blockers, sympatholytic agents) which the researchers will clarify with you.
  • Chronic topical ointment with menthol or capsaicin or use of nasal decongestants.
  • History of surgery with metallic clips, staples or stents.
  • Presence of cardiac pacemaker or other foreign body in any part of the body.
  • History of claustrophobia particularly in a MRI scanner.
  • Had a PET scan done within the past 4 months.

Trial locations and contacts

1 site in 1 country.

Singapore1 site
  • Clinical Nutrition Research Centre

    Singapore, 117599

Other trials in Singapore

About this study

Brown adipose tissue (BAT) thermogenesis can be assessed by IR thermography, the accompanying increase metabolic rate can be measured by whole body calorimetry and BAT volume can be precisely measured by MRI. The aim of the study is to validate IRT for BAT thermogenesis against the present gold standard 18-FDG-PET scan, quantify BAT volume by fat fraction MRI and measure the accompanying increase in BMR by whole body calorimetry among healthy euthyroid subjects.

Read the detailed description

It is now known that human adults do possess viable brown fat in quantities that may be critical for maintenance of a normal basal metabolic rate (BMR) and body weight, dispelling the myth that BAT is only present during infancy for thermoregulation. There are data suggesting that obesity is associated with insufficient BAT. So far the only known and arguably 'gold standard' methodology of BAT imaging in humans is 18-FDG-PET. Yet 18-FDG-PET imaging has significant limitations, given its restricted spatial resolution and its non-trivial level of ionizing radiation (2.8 mSv). The International Commission for Radiological Protection recommends that the radiation exposure for the general public should not exceed 1mSv/year and 1.5 mSv/year from background radiation. In addition, 18-FDG-PET depends on glucose uptake by BAT that does not directly measure its key metabolic activity, namely fatty acid oxidation. Finally, PET scans are very costly. This makes the present gold standard far from ideal as a research tool for investigating BAT physiology. Thus the first objective of this project is to develop an alternative activated BAT imaging method that is not based on ionizing radiation. We are interested in advancing infrared (IR) thermography as a method to assess BAT activity by developing a novel image processing algorithms for IR thermography. Much extant literature describes the use of "average temperature" instead of IR heat flux using the physical principles of radiative heat transfer and thermodynamics to quantify heat from BAT. Also,IR digital still-shots were mostly employed in the past whereas none have reported the analysis of IR flux using a video sequence which more accurately integrates time-varying heat energy output. Without precision in capturing and processing the rich IR data, the value of IR thermography as a tool for BAT research is limited. It is thus crucial to convert the IR images into a readout that reflects energy output. We will thus develop, validate and apply automatic IR image processing with computer software that can efficiently calculate BAT activation. In this proposal we will also improve and validate anatomical fat fraction MRI as a tool for evaluating BAT volumes based on the higher water content in BAT compared with that in WAT. Fat fraction imaging by MRI has been proposed but no proper validation has been done due to the difficulty in matching PET and MRI data on BAT. Instead of using pharmacologic agents (e.g. beta 3-adrenergic receptor agonists such as mirabegron) that can be administered to activate BAT instead of cold stimulus, we will employ capsiate (i.e. capsinoids - non-spicy analogues of capsaicin in peppers and chilies) that have been proven to effectively stimulate BAT in thermoneutral conditions as confirmed by PET scans. We have conducted a preliminary study approved by the DSRB that showed the effectiveness of capsinoids in stimulating BAT. There are publications documenting the use of MRI in distinguishing BAT from WAT, each with their advantages and disadvantages. In this present study, we will perform a proof-of-concept study by simultaneous acquisition of MRI and 18-FDG-PET in a dual-modality fusion MRI-PET scanner available at the Clinical Imaging Research Centre (CIRC) to image BAT in humans, and correlate this with IR thermography of the cervical and supraclavicular regions (SCR) and with metabolic rate accurately measured in a whole body calorimeter. Whole body calorimetry is the real gold standard to assess BAT activity by measuring nonshivering thermogenesis. IR has so far been validated against 18-FDG-PET in mice and rodents, but equivalent validation in humans has not been published. If IR thermography is shown to be equivalent or superior to 18-FDG-PET imaging, it will set a new gold standard in BAT imaging which will be a boon for study of BAT biology in humans.

Being tested
Capsinoids, Cold Stimulus

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CapsinoidsOther

    12 mg of Gel capsules

  • Cold StimulusOther

    Cooling vest maintain at 14 degree Celsius

Study groups in NCT02964442
Study groupRoleWhat they receive
CapsinoidsExperimental8 gel capsules equivalent to 12mg
Receives: Other: Capsinoids
Cooling VestExperimentalUsing Cooling vest (at approxiamately14 degrees Celsius) to cool the body.
Receives: Other: Cold Stimulus

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Brown adipose tissue activation detection by Imaging using 18-FDG-PET/ MRI.

    Measured: post consumption of capsinoids capsules for 2 hours

  2. Energy Expenditure using Whole Body Calorimeter.

    Measured: post consumption of capsinoids capsules for 2 hours

  3. Brown adipose tissue activation detection by Imaging using Infrared Thermography.

    Measured: post consumption of capsinoids capsules for 2 hours

Secondary outcomes (3)
  1. Brown adipose tissue activation detection by Imaging using 18-FDG-PET/ MRI.

    Measured: post cold stimulus up to 2 hours

  2. Energy Expenditure using Whole Body Calorimeter.

    Measured: To measure cold stimulus for 2 hours

  3. Brown adipose tissue activation detection by Imaging using Infrared Thermography.

    Measured: post cold stimulus up to 2 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Nov 2016 (estimated)
  2. Study start23 Oct 2015
  3. Primary completion24 Oct 2023
  4. Study completion24 Oct 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Non-randomised
Intervention model
Single group
Masking
None (open label)
Enrolment
30 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02964442
Sponsor's protocol ID
2015/00715
Other IDs
2015
Acronym
TACTICAL-II
Status last verified
May 2024
First submitted
4 Nov 2016
Last updated
10 May 2024
Results posted
No
Data monitoring committee
No
Individual data sharing
No

Publications

  • Sun L, Yan J, Goh HJ, Govindharajulu P, Verma S, Michael N, Sadananthan SA, Henry CJ, Velan SS, Leow MK. Fibroblast Growth Factor-21, Leptin, and Adiponectin Responses to Acute Cold-Induced Brown Adipose Tissue Activation. J Clin Endocrinol Metab. 2020 Mar 1;105(3):e520-31. doi: 10.1210/clinem/dgaa005.

    PubMed 31912874
  • Sun L, Verma S, Michael N, Chan SP, Yan J, Sadananthan SA, Camps SG, Goh HJ, Govindharajulu P, Totman J, Townsend D, Goh JP, Sun L, Boehm BO, Lim SC, Sze SK, Henry CJ, Hu HH, Velan SS, Leow MK. Brown Adipose Tissue: Multimodality Evaluation by PET, MRI, Infrared Thermography, and Whole-Body Calorimetry (TACTICAL-II). Obesity (Silver Spring). 2019 Sep;27(9):1434-1442. doi: 10.1002/oby.22560. Epub 2019 Jul 13.

    PubMed 31301122
  • Sun L, Camps SG, Goh HJ, Govindharajulu P, Schaefferkoetter JD, Townsend DW, Verma SK, Velan SS, Sun L, Sze SK, Lim SC, Boehm BO, Henry CJ, Leow MK. Capsinoids activate brown adipose tissue (BAT) with increased energy expenditure associated with subthreshold 18-fluorine fluorodeoxyglucose uptake in BAT-positive humans confirmed by positron emission tomography scan. Am J Clin Nutr. 2018 Jan 1;107(1):62-70. doi: 10.1093/ajcn/nqx025.

    PubMed 29381803

Questions about this trial

What is this clinical trial studying?

A study testing Capsinoids and Cold Stimulus in people with Brown Adipose Tissue, run by Singapore Institute of Food and Biotechnology Innovation at 1 site in Singapore.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 10 May 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Brown adipose tissue activation detection by Imaging using 18-FDG-PET/ MRI. (time frame: post consumption of capsinoids capsules for 2 hours). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02964442, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 May 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in